<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30360692</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1423-0380</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>40</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</Title>                <ISOAbbreviation>Tumour Biol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Tamoxifen suppresses paclitaxel-, vincristine-, and bortezomib-induced neuropathy via inhibition of the protein kinase C/extracellular signal-regulated kinase pathway.</ArticleTitle>            <Pagination>                <MedlinePgn>1010428318808670</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1010428318808670</ELocationID>            <Abstract>                <AbstractText>Chemotherapy-induced neuropathy is a highly problematic, dose-limiting effect of potentially curative regimens of cancer chemotherapy. When neuropathic pain is severe, patients often either switch to less-effective chemotherapy agents or choose to discontinue chemotherapy entirely. Conventional chemotherapy drugs used to treat lung and breast cancer, multiple myeloma, and lymphoma include paclitaxel, vincristine, and bortezomib. Approximately 68% of patients receiving these anticancer drugs develop neuropathy within the first month of treatment, and while strategies to prevent chemotherapy-induced neuropathy have been investigated, none have yet been proven as effective. Recent reports suggest that chemotherapy-induced neuropathy is associated with signal transduction molecules, including protein kinase C and mitogen-activated protein kinases. It is currently unclear whether protein kinase C inhibition can prevent chemotherapy-induced neuropathy. In this study, we found that tamoxifen, a protein kinase C inhibitor, suppressed paclitaxel-, vincristine-, and bortezomib-induced cold and mechanical allodynia in mice. In addition, chemotherapy drugs induce neuropathy via the protein kinase C/extracellular signal-regulated kinase pathway in the spinal cord in lumbar segments 4-6 and dorsal root ganglions. In addition, tamoxifen was shown to act synergistically with paclitaxel to inhibit tumor-growth in mice injected with tumor cells. Our results indicated that paclitaxel-, vincristine-, and bortezomib-induced neuropathies were associated with the protein kinase C/extracellular signal-regulated kinase pathway in the lumbar spinal cord and dorsal root ganglions, which suggest that protein kinase C inhibitors may be therapeutically effective for the prevention of chemotherapy-induced neuropathy when administered with standard chemotherapy agents.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Tsubaki</LastName>                    <ForeName>Masanobu</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>1 Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Takeda</LastName>                    <ForeName>Tomoya</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>1 Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Matsumoto</LastName>                    <ForeName>Mikihiro</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>1 Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kato</LastName>                    <ForeName>Natsuki</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>1 Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yasuhara</LastName>                    <ForeName>Shota</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>1 Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koumoto</LastName>                    <ForeName>Yu-Ichi</ForeName>                    <Initials>YI</Initials>                    <AffiliationInfo>                        <Affiliation>1 Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Imano</LastName>                    <ForeName>Motohiro</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>2 Department of Surgery, Kindai University School of Medicine, Osakasayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Satou</LastName>                    <ForeName>Takao</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>3 Department of Pathology, Kindai University School of Medicine, Osakasayama, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nishida</LastName>                    <ForeName>Shozo</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">https://orcid.org/0000-0002-3408-0462</Identifier>                    <AffiliationInfo>                        <Affiliation>1 Division of Pharmacotherapy, Kindai University School of Pharmacy, Higashi-Osaka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Tumour Biol</MedlineTA>            <NlmUniqueID>8409922</NlmUniqueID>            <ISSNLinking>1010-4283</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>094ZI81Y45</RegistryNumber>                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>5J49Q6B70F</RegistryNumber>                <NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>69G8BD63PP</RegistryNumber>                <NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.13</RegistryNumber>                <NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P88XT4IS4D</RegistryNumber>                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006930" MajorTopicYN="N">Hyperalgesia</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008325" MajorTopicYN="N">Mammary Neoplasms, Experimental</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">bortezomib</Keyword>            <Keyword MajorTopicYN="N">chemotherapy-induced neuropathy</Keyword>            <Keyword MajorTopicYN="N">extracellular signal-regulated kinase 1/2</Keyword>            <Keyword MajorTopicYN="N">paclitaxel</Keyword>            <Keyword MajorTopicYN="N">protein kinase C</Keyword>            <Keyword MajorTopicYN="N">tamoxifen</Keyword>            <Keyword MajorTopicYN="N">vincristine</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30360692</ArticleId>            <ArticleId IdType="doi">10.1177/1010428318808670</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>